CCCC Stock Analysis
CC
Uncovered
C4 Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 146 full-time employees. The company went IPO on 2020-10-02. The firm is focused on advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how disease is treated. The company leverages its technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to design and optimize small-molecule medicines that harness the body's natural protein recycling system to rapidly degrade disease-causing proteins. Its TORPEDO platform enables the discovery of targeted investigational small molecule medicines called protein degraders. Its advanced product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma (MM), and non-Hodgkin lymphomas (NHLs). Its other product candidate, CFT8634, is an orally bioavailable BiDAC degrader of a protein target called BRD9 for the treatment of synovial sarcoma and SMARCB1-null solid tumors.